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PresenilinAlzheimer's disease is the most prevalent form of neurodegenerative disease. Despite many years of intensive
research our understanding of the molecular events leading to this pathology is far from complete. No effective
treatments have been deﬁned and questions surround the validity and utility of existing animal models. The
zebraﬁsh (and, in particular, its embryos) is a malleable and accessible model possessing a vertebrate neural
structure and genome. Zebraﬁsh genes orthologous to thosemutated in human familial Alzheimer's disease have
beendeﬁned.Work in zebraﬁsh has permitteddiscovery of unique characteristics of these genes thatwould have
been difﬁcult to observe with other models. In this brief review we give an overview of Alzheimer's disease and
transgenic animalmodels before examining the current contribution of zebraﬁsh to this research area. This article
is part of a Special Issue entitled Zebraﬁsh Models of Neurological Diseases.raﬁsh Models of Neurological
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Alzheimer's disease (AD) is the most common form of neurodegen-
erative disease. Globally, the incidence of dementiawas estimated in2001
to be 24.3 million with an estimated increase to 81.1 million in 2040 [1].
Clinically, AD is characterised byprogressivememory loss and can include
impairment of speech andmotor ability, depression, delusions, hallucina-
tions, aggressive behaviour and, ultimately, increasing dependence upon
others before death (recently reviewed by Voisin and Vellas [2]). The
major neuropathological hallmarks of the disease were ﬁrst described by
Alois Alzheimer as “ﬁbers” and “small military” foci (English translation,
[3]) Today these are commonly referred to as neuroﬁbrillary tangles
(NFTs) and amyloid plaques. Neuroﬁbrillary tangles are hyperpho-
sphorylated forms of the tau protein, while themajor protein component
of amyloid plaques is a small peptide referred to as amyloid beta (Aβ).
Other forms of lesion have also been found in AD brains (reviewed by
Duyckaerts et al. [4]).
Alzheimer's disease can be classiﬁed broadly into two groups, late
onset AD (LOAD, occurring N65 years) and early onset AD (EOAD,
occurring b65 years). LOAD accounts for the vast majority of AD cases
(95%) and is associated with many risk factors. It is well established that
age and possession of the ε4 allele of the APOLIPOPROTEIN gene (APOE ε4)
are themajor risk factors formost of the population (reviewed byMartins
et al. [5]). However, other risk factors such as hormonal changes
associated with ageing, diet and lifestyle factors play very important
roles. Cardiovascular risk factors such as hypercholesterolemia, increasedLDL and reduced HDL levels, hypertension, obesity and type II diabetes
make important contributions to the risk of developing AD (reviewed by
Martins et al. [5]). Genome-wide association studies in humans have
identiﬁed a number of possible additional loci associated with risk for
LOAD (reviewedbyRademakers andRovelet-Lecrux [6]. In particular, two
recent studies identiﬁed overlapping sets of candidates (see [7,8] and
Table1). Individuals carrying the APOE ε4 allele also bear some risk of
developing the early onset form of AD. Overall, EOAD accounts for only a
small percentage of AD cases but is the most severe form of the disease.
The majority of EOAD cases are familial forms of AD showing dominant
inheritance.
Familial AD (FAD) is typically associated with an early age of onset
as young as 25 years (reviewed by Verdile and Martins [20]). Most of
our knowledge of the molecular events underlying the development
of Alzheimer's disease comes from FAD since we can use genetic
analysis to identify the genes and proteins involved. Mutations at only
three loci are known to cause FAD although other loci may yet be
found (see review by Rademakers and Rovelet-Lecrux [6]). One locus
hosts the Amyloid Precursor Protein (APP) from which Aβ is cleaved
by the action of two “secretases,” β-secretase and γ-secretase (see
Fig. 1). Mutations in APP alter these cleavages so that Aβ production is
increased or more aggregation-prone forms of Aβ are formed
(reviewed by Verdile et al., [20]). The remaining two loci host the
presenilin genes PSEN1 and PSEN2 with mutations in these genes
accounting for 50–70% of EOFAD cases [21]. The presenilin proteins
form the catalytic core of protein complexes with γ-secretase activity.
Mutations in the presenilins also appear to alter the rate or form of Aβ
production and many LOAD associated risk factors also regulate Aβ
levels in the brain. Therefore, it is not surprising that the currently
dominant hypothesis for the cause of FAD (and LOAD) is the “amyloid
hypothesis” that postulates that toxic oligomerisation of Aβ is the
initiating factor beginning a cascade of consequences such as synaptic
Fig. 1. The γ-secretase complex consists of four protein components including PSEN1 or
PSEN2 that residewithin lipid bilayers and cleave type 1 transmembrane domain proteins
at a catalytic site dependent upon two aspartate residues (stars). APP is initially cleaved
either by α- or β-secretase to produce APPα or APPβ. Only β-secretase cleavage permits
Aβ peptide production after secondary cleavage by γ-secretase that also releases APP's
intracellular domain that can enter the nuclear to contribute to gene regulation.
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dysfunction, degeneration and death (see review in [22]).
The amyloid hypothesis is an attractively parsimonious explanation
for AD pathogenesis and ﬁnds support from numerous phenomena
observed in EOFAD and LOAD brains. However, it fails to explain some
observations in animalmodels and the outcomes of a number of human
clinical trials of drugs intended to ameliorate Aβ toxicity. For example,
the majority of transgenic mice harbouring FAD-causing mutations
leading to accumulation of human Aβ in their brains do not show
dramatic neurodegeneration [23] (see the discussion in the 2008 paper
by Chen et al. [24]). However, these transgenic mice do show cognitive
deﬁcits in behavioural tests and show reduction in long-term
potentiation, most likely indicating loss in synaptic activity [25]. To
obtain signiﬁcant neurodegeneration or neuronal loss in transgenic
mice requires expression of three or more mutations in AD-associated
genes. Examples ofmouse ADmodels used currently include “3xTg-AD”
micebearingmutant alleles of PS1,APP andMAPT [26] and “5xFAD”mice
bearing three APP and two PS1 mutant alleles [27]. However, the co-
existence of three or more mutations in AD-associated genes is not a
situation that occurs in humans. Amore physiologically relevant animal
model is required thatmore closely mirrors human AD neuropathology
including the observed neurodegeneration and neuronal loss (see the
critical review by Buxbaum [28]).
A number of therapeutic agents aimed at reducing Aβ production or
accumulation/aggregation have failed human clinical trials. These include
peptidemimetics that inhibit Aβ aggregation (i.e., Alzhemed™,) or agents
that either inhibit γ-secretase activity (e.g. LY-411,575 and LY-450,139 )
or target the production of the more neurotoxic Aβ42 (e.g. the NSAID,
Flurizan™ and refer to www.alzforum.org regarding information on AD
drugs in clinical trials). This has raised questions over the validity of the
amyloid hypothesis. However, issues surrounding penetration through
the blood–brain barrier and the advanced state of neurodegeneration
when these drugs were given may explain their failure. Apparently
successful therapeutics currently in phase II/III trials such as the
immunotherapeutics Bapinezuimab™ and Solabezumab™ or agentsdirected at neutralising Aβ toxicity (i.e. PBT2) are addressing such issues
(reviewed by Wisniewski, 2009 [29]). There are also therapies not
directed at Aβ that show promise including the anti-histamine Latre-
pirdine (formerly known as Dimebon™) which has completed phase IIIa
trials and is currently in IIIb trials [30]. The mechanism(s) underlying the
beneﬁts of Latrepirdine is unclear but may include improving mitochon-
drial activity. Another agent that has shown some promise is Rember™
(methylthionium chloride) which reduces tau aggregation (see http://
www.taurx.com/) although this drug was not seen to affect the
histological or behavioural phenotypes of transgenic zebraﬁsh expressing
mutant human MAPT (see 2009 ICAD conference report at www.
alzforum.org/new/detail.asp?id=2203). Methylthionium chloride is bet-
ter known to those working with zebraﬁsh as methylene blue which is
used to inhibit fungal growth and to stain the yellowpteridine-containing
pigment cells of ﬁsh, xanthophores [31]. Recently, the combination of
Dimebon (Latrepirdine) and methylene blue has also been shown to
inhibit aggregation of TDP-43 [32], a protein component of ubiquitinated
inclusions found in the neurodegenerative diseases amyotrophic lateral
sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) (reviewed
by Mackenzie [33]). The beneﬁcial outcomes of these non-Aβ directed
agents may provide further evidence for alternatives to the amyloid
hypothesis, However, it is conceivable that these agents may be acting to
ameliorate the consequences of Aβ toxicity e.g. by protecting neurons
from insults such as aggregation of Aβ or other proteins.
2. Presenilin activity is involved in many aspects of AD pathology
Thepresenilinsproteins are known to interactwithboth theAPP and
tauproteins [34–38]providingonepossible linkbetweenAβproduction
and changes in tau phosphorylation. Mice lacking expression of both
Psen1 and Psen2 in forebrain tissue show anumber of phenotypic effects
resembling Alzheimer's disease, i.e. neurodegeneration such as hyper-
phosphorylation of tau, formation of intracellular tau inclusions, gliosis,
expansion of brain ventricles and neuronal death all in the absence of
any Aβ production [24]. Some characteristics of Alzheimer's disease,
such as increased formation of glia, may result from changes in
presenilin activity since γ-secretase complexes cleave not only APP
but also a large collection of other transmembrane proteins such as
NOTCH, E-cadherin, neuregulin-1 and syndecan (reviewed in Ref. [39]).
Presenilins also function in a number of cellular processes, at least some
of which appear independent of γ-secretase activity. For example, Kang
et al. [40] showed that mouse Psen1 represents a second pathway for
phosphorylation of β-catenin independent of Axin. Presenilins also
appear to act as Ca2+ leak channels in the endoplasmic reticulum [41].
Presenilins are also found in interphase kinetochores [42] (although
this observation has not been replicated) and changes in presenilin
activity can cause aneuploidy ([43,44]) and dysregulation of cell cycle
proteins [12,45]. Indeed, the activity in γ-secretase of at least some of
the proteins comprising these complexes does not appear to be their
original function. Homologues of presenilins exist in plants and this
kingdom does not display γ-secretase activity [46].
The greatmajority of themutations causing FAD are found in PSEN1.
Currently over 180 different missense mutations are known (data on
mutations are collated at Alzheimer Disease and Frontotemporal
Dementia Mutation Database, http://www.molgen.ua.ac.be/ADMuta-
tions/). There is also evidence that oligomeric forms of Aβ can feed back
onto the activity of γ-secretase ([47]). Thus it is possible that mutations
that cause production of more Aβ, or more aggregation-prone forms of
Aβ, may affect presenilin function and that changes in presenilin
function may then affect tau phosphorylation, cell differentiation (e.g.
via Notch signalling), calcium homeostasis, etc.
3. Using zebraﬁsh to study genes mutated in FAD
Mice are the dominantmodel used formodelling of Alzheimer's disease
pathology (reviewed inRef. [48]) but non-mammalian organismshave also
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ﬁrst showed the connection between the presenilins and Notch signalling
[49,50]. Expression of human Aβ in C. elegans [51] and Drosophila [52] has
been seen to cause amyloid deposits in muscle and neurodegeneration
respectively. Aβ toxicity can also be studied using yeast [53]. Use of these
organisms has opened up possibilities for screening drug libraries to ﬁnd
compounds blocking Aβ toxicity.
As a model organism, zebraﬁsh presents many advantages for the
study of human disease. The vertebrate zebraﬁsh genome and anatomy
show only ~420 million years (Myr) of divergence from the human
lineage [54] rather than the ~600 Myr of the ecdysozoans (Drosophila
and C. elegans, [55]). Therefore, most human genes have clearly
identiﬁable orthologues in zebraﬁsh (however, a genome duplication
early in the teleost (bony ﬁsh) lineage means that, in many cases, two
zebraﬁsh genes together perform the function of an orthologue). The
numerous and externally fertilized embryos of zebraﬁsh are easily
amenable tomethods formanipulating geneandprotein activity suchas
injection of antisense oligonucleotides, mRNAs or transgenes and they
can be arrayed in microtitre plates for screening of drug libraries. Cell
labellingand transplantation for tracking thebehaviour and interactions
of living cells is also routine. A good indication of the potential utility of
zebraﬁsh for Alzheimer's disease research is the attempts to obtain
patent coverage of wide areas of the ﬁeld (e.g. WO/2006/081539).
Zebraﬁsh possess genes orthologous to all the genes known to be
involved in Alzheimer's disease (Table 1) The genes appa and appb [9]
are duplicates of an ancestral teleost orthologue of human APP. The
genes psen1 [11] and psen2 [16] are orthologues of human PSEN1 and
PSEN2, respectively. Our laboratory has also identiﬁed duplicates of an
ancestral teleost orthologue of the MAPT gene encoding tau protein,
mapta and maptb [56] (discussion of tau activities in zebraﬁsh
including the MAPT-based model of neurodegeneration of Paquet et
al. 2009 [57] is to be found in an accompanying paper by Ed Burton).
The body of research literature examining the endogenous zebraﬁsh
appa, appb, psen1 and psen2 genes is still quite limited. Musa et al. [9]
detected widespread and overlapping transcription of both appa and
appb bywholemount in situ transcript hybridisation (WISH) frommid-
gastrulation. Later in development these two genes show differing
patterns of transcription but, notably, at 24hpf both are expressed in the
developing forebrain (telencephalon) and ventral diencephalon. In
addition, appb is expressed in the ventral mesencephalon, a series of
nuclei in the hindbrain and in the spinal cord. Joshi et al. [10] recently
examined the effects of reduction of appb function through use of
antisensemorpholino oligonucleotides blocking translation (while they
also attempted to reduce appamRNA translation it is not clear that theyTable 1
Zebraﬁsh genes orthologous to those involved in Alzheimer's disease.
Zebraﬁ
Loci for dominant mutations in FAD
Amyloid Precursor Protein (APP) appa
appb
Presenilin 1 (PSEN1) psen1
Presenilin 2 (PSEN2) psen2
Loci associated with risk for ADa
Apolipoprotein E (APOE) apoeb
Microtubule-Associated Protein Tau (MAPT) mapta
maptb
Clusterin (CLU) Clu
Phosphatidylinositol Binding Clathrin Assembly Protein (PICALM) picalm
Complement Component (3b/4b) Receptor 1 (CR1) Unknow
Loci for γ-secretase complex members
Nicastrin (NCT) ncstn
Anterior Pharynx Defective 1 Homolog A (APH1a) unknow
Anterior Pharynx Defective 1 Homolog B (APH1b) aph1b
Presenilin Enhancer 2 (PSENEN) psenen
a A large number of additional associated genes have been reported and are reviewed inwere able to do this. Also, their appb analysis utilized only one
morpholino so non-speciﬁc effects are not excluded). They observed
defective convergent extension movements and reduced body length.
Interestingly, injection into zebraﬁsh embryos of mRNA encoding
normal human APP was more effective at ameliorating the loss of
appb translation than an Alzheimer'smutant form (“APPswe” containing
the “Swedish” double mutation K595N with M596L [58]). This
demonstrates that zebraﬁsh embryos can be exploited for analysis of
differences in the activity of different mutant forms of APP [10].
Two papers examining transcriptional control of appb have been
published [59,60]. Both emphasise the importance for expression of a
regulatory element in the ﬁrst intron of the gene. Approximately 14
kb of DNA from the promoter region and ﬁrst intron of the gene can
largely recapitulate the embryonic transcription pattern of appb [59].
Attempts to model Aβ toxicity have, so far, proven difﬁcult and no
studies have yet been published. The existence of transgenic ﬁsh
expressing human APPswe in neurons in zebraﬁsh the under the control
of the promoter of the elavl3 gene (previously known as HuC) was
reported at the 6th European Zebraﬁsh Development and Genetics
Meeting in Rome in July 2009 (Hruscha, Teucke, Paquet, Haass and
Schmid) but there is no data yet on any toxic effects. In our laboratories
we have followed a number of approaches to analysing Aβ toxicity.
Simple incubation of zebraﬁsh embryos inmedia containing Aβ peptide
appears to produce effects on neural development as monitored by
changes in the patterns of neurons observed in non-transgenic
zebraﬁsh. It can also induce cell and embryo death (Frederich-Sleptsova
et al. manuscript in preparation). We also attempted to generate a
transgenic zebraﬁsh model to facilitate screening for drugs suppressing
Aβ toxicity by expressing the 42 amino acid residue form of human Aβ
(Aβ42) in the melanophores (melanocytes) that constitute the zebra-
ﬁsh's dark surface stripes. The hope was to create a highly visible but
nevertheless viable phenotype in zebraﬁsh larvae that could then be
arrayed in microtitre dishes for exposure to various chemical com-
pounds. For this we used a DNA fragment from the promoter of the
zebraﬁsh gene mitfa (previously nacre) that can speciﬁcally drive
transcription in zebraﬁsh melanophores [61]. This was coupled to DNA
coding for a secretory signal fused to Aβ42. Unfortunately, ﬁsh bearing
this transgene only showed a disturbed pigmentation pattern at 16
months of age—too late for use in drug screening [81].
Analysis of presenilin function in zebraﬁsh has tended to focus on
psen1 due to the more frequent role played by mutations of its human
orthologue, PSEN1 in AD. Zebraﬁsh psen1 sequence and activity were
ﬁrst analysed by Leimer et al. in 1999 [11] who noted extensive















Rademakers and Rovelet-Lecrux, 2009.
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When zebraﬁsh Psen1 protein expression was driven at high levels in
cultured human HEK293 cells the zebraﬁsh protein (as expected)
displaced human PSEN1 from γ-secretase complexes indicating
sufﬁcient structural conservation to interact with other complex
components. However, the C-terminal fragment (CTF) of zebraﬁsh
Psen1 generated by the endoproteolysis of the holoprotein (required to
activate γ-secretase activity [62]) is sufﬁciently different in size that it
can be distinguished from the CTF of human PSEN1 on western blots.
Also, zebraﬁsh Psen1 possesses sufﬁcient primary structural differences
from human PSEN1 that its γ-secretase cleavage of APP was abnormal
leading to increasedproduction of Aβ42 relative to production of the less
aggregation-prone 40 amino acid residue form of Aβ (Aβ40). These
authors also demonstrated that mutation of one of the two critical
catalytic aspartate residues in zebraﬁsh Psen1 could abolish its γ-
secretase activity.
As expected from the expression of the psen1 transcript, we showed
that Psen1 protein can be observed from the earliest stages of
development [14]. Interestingly, this did not appear to be the case for
zebraﬁsh psen2 that we identiﬁed in 2002 [16]. We detected the
ubiquitous presence of psen2 transcripts at all stages but an antibody
raised against an oligopeptide corresponding to N-terminal fragment
(NTF) sequence from Psen2 protein only revealed higher expression of
Psen2 after 6 hpf [16]. However, there is evidence from humans [63,64]
and from our own unpublished work of alternative splicing and
phosphorylation of PSEN2 orthologous proteins so we presume that
species of zebraﬁsh Psen2 protein do, in fact, exist at the earliest
developmental stages in this organism.
The essential role of presenilin activity in Notch signalling during
development and the resorption of dead embryos that occurs in mice
has hindered the analysis of the roles of presenilin during vertebrate
development. Resorption is not a problem in zebraﬁsh so we have been
keen to exploit morpholino antisense technology to block the activity of
the zebraﬁsh psen1 and psen2 genes. In mice, loss of Psen1 activity is
lethal during development and Psen1−/− embryos show a similar
phenotype to those lacking mouse Notch1 activity [65,66]. In contrast,
mouse Psen2−/− embryos are viable with no obvious developmental
defects [67,68] (although adults do display haemorrhaging and
histological changes in lung tissue [69]. However, mice lacking both
Psen1 and Psen2 activity have a more severe phenotype and loss of γ-
secretase activity thanwhenonly Psen1 activity is absent [67].Whenwe
blocked psen1 translation in zebraﬁsh we observed similarly irregular
delineation of somites to that seen in Psen1−/−mouse embryos and the
cyclic expression of the her1 gene that controls somite formation was
disturbed in the presomitic mesoderm [13]. Interestingly, blockage of
translation of zebraﬁsh psen2 transcripts also produces signiﬁcant
changes in embryodevelopment including expansionof brain ventricles
at 48 hpf and decreased trunk neural crest formation with increased
numbers of neurons at 24 hpf. The latter two defects at least can be
attributed to decreased Notch signalling indicating that Psen2 in
zebraﬁsh plays a more prominent role in Notch signalling than its
mammalianorthologue [15]. Indeed, in unpublishedwork, vanTijn et al.
[70] have shown that zebraﬁsh homozygous for null mutations in psen1
are, nevertheless, viable and fertile indicating that psen2 activity can
satisfy all essential psen1 functions, at least in a laboratory setting.
The viable homozygous null psen1 mutant zebraﬁsh of van Tijn et
al. [70] show decreased cell proliferation and de novo neurogenesis.
Such ﬁsh also present an opportunity for in vivo analysis of the effects
on psen1 function of mutations causing Alzheimer's disease [70,71].
Since presenilin proteins are ubiquitously expressed, simple ubiqui-
tous transgenic expression of mutated psen1 genes in ﬁsh lacking
endogenous psen1 activity can allow analysis of their function in vivo.
The ability to analyse the function of genes involved in FAD in vivo is
important since gene regulatory and functional data from cultured cells
and in vitro assays is sometimes not consistent with what occurs in the
whole organism. Thismay bedue to genetic and epigenetic changes thatoccur in cultured cells during successive passages and/or immortalisa-
tion. Also, cultured cells exist in a highly abnormal environmentwithout
the normal three-dimensional context of cellular contact and signalling.
This may explain, to some extent, differences that we have observed
while analysing the function of presenilins in zebraﬁsh embryos
compared to what has been observed from mammalian cell culture.
For example, when we overexpressed Psen2 protein in zebraﬁsh
embryos at relatively high levels by mRNA injection we did not see a
decrease in Psen1 levels [13] whereas transfection of constructs
expressing presenilin proteins into cultured mammalian cells is
known to reduce the levels of endogenous presenilin proteins [72].
A fertilized zebraﬁsh egg represents a macroscopic single cell in
which the activity of one ormultiple endogenous genes/proteins can be
subtly manipulated to obtain a phenotypic or biochemical readout. We
attempted tomodel themolecular effects ofmutations that alter human
PSEN1 splicing to cause FAD by altering the splicing of zebraﬁsh psen1
using injected morpholino antisense oligonucleotides. Mutations
causing increased levels of a PSEN1 transcript isoform lacking exon
8 or that cause loss of exon 9 can cause a form of FAD with a peculiar
histology of plaques lacking neuritic cores and showing a “cotton wool”
morphology [73,74]. Unfortunately, when morpholinos binding over
the splice acceptor sites of zebraﬁsh exons cognate to human exon 8 or
exon 9 were injected we did not observe the desired exon loss from
transcripts. Instead we saw inclusion of cognate introns 7 or 8,
respectively, in a proportion of transcripts causing truncation of the
open reading frames after exons 7 or 8. Interestingly this produced very
strong dominant negative effects in the case of truncation after exon 7
sequence but not for truncation after exon 8 (which is very similar to a
normal Psen1 NTF). The dominant negative effects included cross-
inhibition of psen2 activity [14]. Injection of mRNAs encoding Psen1
proteins truncated after exon 7 or exon 8 sequences produced similar
results ([14] and unpublisheddata). Testswith furthermorpholinos and
mRNAs have shown that transcripts producing dominant negative
truncatedproteins are those that code for part or all of sequence cognate
to human PSEN1 exons 6 and 7 but not exon 8. (Curiously one of two
nonsense mutations in zebraﬁsh psen1 currently under analysis in the
laboratory of Dana Jongejan-Zivkovic falls in this region but there
appears to be no dominant negative effect probably due to nonsense
mediated decay of the transcript before it can be translated into a
truncated protein. (Jongejan-Zivkovic personal communication). The
discovery of potently dominant negative forms of truncated presenilin
may be important since it has been suggested that a unifying feature of
all the 180+ mutations in human PSEN1 may be that they are
hypomorphic with respect to γ-secretase activity [75]. It is possible
that the truncated forms of numerous proteins that are seen to
accumulate in the brains of LOAD individuals may represent a failure
of RNA quality surveillance mechanisms such as nonsense mediated
decay [76]. This, combinedwith increased rates of aberrant splicing, etc.
seen in aged cells [77] may allow accumulation of dominant negative
truncated forms of presenilin in ageing brains that could suppress γ-
secretase activity and thus contribute to LOAD.
A zebraﬁshmodel of FADor LOADwould be very useful for screening
for drugs to prevent or ameliorate these diseases. However, even
embryo development in non-transgenic zebraﬁsh can provide assays
for the actions of drugs relevant to Alzheimer's disease. The drug N-[N-
(3,5-diﬂuorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester (DAPT,
[78]) is now commonly used to inhibit γ-secretase activity in zebraﬁsh
[79]. Unfortunately, it is commonly and incorrectly assumed to be
blocking only Notch signalling which, while very important, is not
the only inﬂuential signalling pathway facilitated by γ-secretase. For
example, as noted above, Joshi et al. [10] showed that inhibition of appb
activity causes aberrant convergence-extensionmovements although it
has not been shown that γ-secretase activity is required for this
and treatment with DAPT [79,15] or simultaneous inhibition of
translation of both Psen1 and Psen2 by morpholino injection [15]
does not produce this effect.Wehavepreviously shown thatnumbers of
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(DoLA) interneuron, appear dependent upon Psen2 but not Psen1
activity [14,15]. We used this as an assay for Psen2 activity to show that
truncated Psen1 could suppress Psen2 activity [14]. Finally, in a
publication from the Xia laboratory, Yang et al. [80] used zebraﬁsh
embryos to observe the differential effects on development of drugs
inhibiting primarily theAPPorNOTCH cleavage activities ofγ-secretase.
Thus, zebraﬁsh embryos can provide a valuable tool for discovery of
additional compounds that show differential inhibitory effects on γ-
secretase. The Xia laboratory has also used injection of different
combinations of morpholino antisense oligonucleotides to analyse
the effects of inhibiting translation of additional protein components of
γ-secretase complexes such as aph1b (orthologous to human APH1B)
and psenen (orthologous to human PSENEN and previously named
PEN2). In this way they demonstrated that zebraﬁsh Psenen inter-
acts with NF-kappaB [19] and the p53-dependent apoptosis pathway
[18].
4. Concluding remarks
Despite many years of intensive research uncertainty still surrounds
the fundamental mechanisms underlying AD pathology. There is
considerable doubt about the relevance of existing transgenic mouse
models of the disease. Our lack of understanding has slowed the
developmentof therapies to treat or preventAD. The vertebrate genome
and neurobiology of zebraﬁsh and our rapidly expanding ability to
manipulate gene activity in this organism offer alternative pathways in
which to probe the mysteries of AD pathology. In particular, zebraﬁsh
are well suited to biochemically-based approaches whereby gene
activities are manipulated transiently and then the consequences
examined in an otherwise normal cellular environment. As genome-
wide association studies reveal additional genes involved with
development of AD pathology these biochemically-based approaches
can rapidly contribute to our understanding of the relevance of these
genes while reducing the chance of being misled by experimental
results from tissue culture systems that may not reﬂect in vivo reality.
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